Clinical Trials

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05940493 2026-03-13

Abemaciclib in Newly Diagnosed Meningioma Patients

72 enrolled

CNS

Meningioma

NCT05708235 2026-03-05

MiRaDoR

976 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8

NCT02693535 2026-02-13

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT06678269 2026-02-12

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Phase 1 Recruiting

28 enrolled

Breast Neoplasms

NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

32 enrolled

Endometrial Neoplasms

NCT04923542 2026-02-06

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

31 enrolled

CNS

Brain Neoplasms

NCT05305924 2026-01-28

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

28 enrolled

ER-Positive Breast Cancer

NCT05933395 2026-01-20

GERTRUDE

135 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06835972 2026-01-15

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

43 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05501704 2026-01-07

ETHAN - ET for Male BC

Breast Neoplasms, Male

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT06139107 2025-11-14

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Phase 1 Recruiting

15 enrolled

Breast Neoplasms

NCT02977780 2025-11-10

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

460 enrolled

CNS

Glioblastoma

NCT05608252 2025-10-29

VS-6766+Abema+Fulv in Met HR+/HER- BC

63 enrolled

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

174 enrolled

Breast Neoplasms

NCT07190443 2025-09-29

AURA

Phase 3 Recruiting

290 enrolled

Breast Neoplasms

NCT04305834 2025-09-24

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

43 enrolled

Breast Neoplasms

NCT05113537 2025-09-18

UPLIFT

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT04486352 2025-09-04

EndoMAP

148 enrolled

Endometrial Neoplasms

NCT06365788 2025-09-04

ABBICAR

53 enrolled

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

NCT07151911 2025-09-03

ROYAL

Recruiting

100 enrolled

Breast Neoplasms

NCT03310879 2025-09-02

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

38 enrolled

Tumor-Agnostic

Neoplasms

NCT04469764 2025-07-29

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

32 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04040205 2025-07-20

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Other solid neoplasmSarcoma

44 enrolled

Chondrosarcoma, Retinoblastoma, Sarcoma, Osteosarcoma

NCT03675893 2025-06-15

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

180 enrolled

Ovarian Neoplasms, Endometrial Neoplasms

NCT04614194 2025-06-02

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

Breast Neoplasms

NCT05362760 2025-05-16

MINERVA

Phase 4 Recruiting

300 enrolled

Breast Neoplasms

NCT04523857 2025-04-04

ABBY

66 enrolled

Breast Neoplasms

NCT05095207 2025-04-02

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

42 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06594679 2025-03-28

NICHOL

73 enrolled

Ovarian Neoplasms

NCT06259929 2025-02-18

Neo-AGILE

51 enrolled

Breast Neoplasms

NCT06805812 2025-02-03

PALMARES-2

Recruiting

3,500 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT05159245 2024-07-15

FINPROVE

Other hematologic neoplasm

250 enrolled

Hematologic Neoplasms

NCT06341621 2024-04-10

Rainbow

Phase 3 Recruiting

1,900 enrolled

Breast Neoplasms

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

766 enrolled

Breast Neoplasms

NCT05766410 2023-03-16

ORACLE-RIPA